Recent Approval for Million-Dollar Sickle Cell Treatments Raises Questions and Concerns About Accessibility for Those Most Affected, Advocate Says
It’s been a month since the Food and Drug Administration greenlit two gene therapies for people battling sickle cell disease. The news opened a glimmer of hope, but many questioned the accessibility of the treatments. For Andrea Hall, the new authorization of breakthrough treatments, Casgevy by Vertex Pharmaceuticals and Lyfgenia by Bluebird bio, is a stride…
